1st Transnational Call the European One Health Partnership - Antimicrobial Resistance
-
Topics
Science Calls Horizon Europe
-
Share
The One Health - Antimicrobial Resistance (OH-AMR) European Partnership, which includes the Foundation for Science and Technology (FCT), is launching its first joint transnational Call for funding for research and innovation projects on November 18th, under the theme "New treatments to tackle AMR". This Call involves the participation of funding institutions from 28 countries and aims to support projects that contribute to developing new approaches to combating antimicrobial resistance.
Research and innovation proposals submitted to the Call must focus on one of the following themes:
- Identify and develop new combination treatments, using existing or innovative antimicrobials, or the combination of antimicrobials with complementary treatments, with the aim of prolonging the effectiveness of drugs and combating resistance.
- Develop tools and methods to improve adherence to treatment protocols.
- To assess the impact of the use of antimicrobials in veterinary medicine and agriculture on the risk of transmitting antimicrobial resistance (AMR) to humans and the environment, with a view to informing policies that restrict the use of certain antimicrobials in human medicine.
Applications can be submitted from November 18, 2025 to February 2, 2026, until 12 noon (mainland Portugal time). To support potential applicants, an informativewebinar will be held on November 26 at 13:00 (mainland Portugal time).
More information about the Call is available on the partnership page and additional information will be published after the launch.
The OH-AMR Partnership is co-funded by the Horizon Europe program and promotes an integrated One Health approach, involving human, animal, plant and environmental health, with the aim of preventing and controlling antimicrobial resistance (AMR). It brings together 53 organizations from 30 countries, including Portugal, represented by FCT and the Agency for Clinical Research and Biomedical Innovation (AICIB).